NEW HAVEN, Conn., Sept. 17, 2007 (PRIME NEWSWIRE) -- Achillion Pharmaceuticals, Inc., (Nasdaq:ACHN) a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, Chief Executive Officer of Achillion, will present a corporate overview and update on the Company's clinical programs in HIV, HCV and serious bacterial infections at the First Annual Maxim Group Growth Conference. The Company presentation will take place on Thursday, September 20, 2007 at 8:30 a.m. EST at the Grand Hyatt Hotel, New York.
